Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1
- 15 February 2007
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 107 (1) , 95-102
- https://doi.org/10.1007/s10549-007-9522-y
Abstract
We aimed to investigate the role of CCND1 G870A polymorphism genetic and transcriptomic effects susceptibility in association with breast cancer carcinogenesis and clinical prognosis. A case-control study was conducted with the enrollment of 992 sporadic breast cancer patients and the corresponding 960 normal controls from routine mammographic or sonographic screening for breast cancer between 1995 and 2003 in Taiwan. The 167 fragment spanning the G870A polymorphism in exon 4-intron 4 boundary was amplified to identify genotype of CCND1 (G870A) polymorphism. Competitive RT-PCR were further performed to investigate alternative transcript in four different specimens in association with immunohistochemistry markers. The results showed that AG and AA subgroup were at increased risk for developing breast cancer compared with the GG genotype by 19% (OR 1.19 (0.85–1.67)) and by 34% (OR 1.34 (0.04–1.74)), respectively. A870 allele revealed a recessive tendency while GG and AA/AG subgroup was compared (OR 1.35 (1.07–1.70)). AA genotype also had a higher risk in premenopausal women than postmenopausal ones. The recurrence-free survival was longer in patients with GG+AG than that in patients with AA (P = 0.034). A870 allele produced more transcript b both in malignant. There were significant correlations between several immunohistochemistry markers (such as Ki-67) and cyclin D1 or CDk4. We concluded CCND1 G870A polymorphism make significant contribution to breast cancer in the country with the preponderance of breast cancer in young women. The role of G870A polymorphism in alternative transcript was not only implicated in CCND1 alternative splicing but also correlated with immunohistochemistry markers.Keywords
This publication has 35 references indexed in Scilit:
- Inhibition of Smad Antiproliferative Function by CDK PhosphorylationCell Cycle, 2004
- Cancer Cell CyclesScience, 1996
- Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection ofcyclin D1 in breast andcyclin E in ovarian tumorsInternational Journal of Cancer, 1996
- Cyclin D1 and prognosis in human breast cancerInternational Journal of Cancer, 1996
- Absence of cyclin D1/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphismCancer Letters, 1995
- D-type cyclinsTrends in Biochemical Sciences, 1995
- Cyclin D1 protein expression and function in human breast cancerInternational Journal of Cancer, 1994
- PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.Proceedings of the National Academy of Sciences, 1991
- Characterization of a candidate bcl-1 gene.Molecular and Cellular Biology, 1991
- A novel cyclin encoded by a bcl1-linked candidate oncogeneNature, 1991